Click on the "SHOP" tab to order your CBD products today.



Proprietary CBD Capsule Formulation to Address Neuropathic Pain

Proprietary CBD Capsule Formulation to Address Neuropathic Pain

Endexx Initiates Adaptive Clinical Study With Proprietary CBD Capsule Formulation to Address Neuropathic Pain Endexx Corporation (OTC PINK: EDXC), a provider of innovative hemp derived phyto-nutrients and nutritional products, has announced the launch of a doctor supervised, adaptive clinical study to test the efficacy of its proprietary CBD capsule in response to patients suffering from neuropathic pain. Dr. Martin Pressman, DPM in New Haven, Connecticut, Dr. Daniel Brandwein, DPM in Weston, Florida, Dr. Michael Horwitz, DPM and Dr. Daniel Kiddy, DPM, both in St Louis, Missouri will enroll twenty patients into four groups, for a one month study using CBD enriched capsules to evaluate neuropathic pain reduction. The proprietary formulations are pharmacist formulated and manufactured capsules which include a dual pack as a day and night formula with cannabidiol as its primary active ingredient. Each patient will be taking two capsules a day with results to be monitored. At the end of the study, findings will be subjected to an independent peer review board. This study is an extension of the work conducted by Dr. Kiddy with his patients and a follow up of Dr. Brandwein’s research that demonstrated an average pain reduction after 2 weeks of usage from 7 to 8 down to 3 to 4 on a pain scale of 1 to 10, using 4 to 5 drops of CBD-rich hemp oil twice a day. Dr. Brandwein stated, “I am very excited about the upcoming new trial where we can follow the information even closer. I also believe that in a capsule form, patients will be more compliant and have better results. In some cases, my patients have decreased and discontinued their usage of Neurontin and Gabapentin.”
  • Andy V
Researchers Find Cannabidiol Shows Promise in Treating Schizophrenia

Researchers Find Cannabidiol Shows Promise in Treating Schizophrenia

A new study from Western University demonstrates that Cannabidiol (CBD), affects the brain in a way that makes it an ideal treatment option for schizophrenia. This research comes on the heels of a findings from the same lab that show adolescent exposure to THC, the other major compound found in marijuana, may lead to the onset of schizophrenia in adulthood.

“CBD is acting in a way that is the exact opposite to what THC is doing,” said Steven Laviolette, PhD, associate professor at Western University’s Schulich School of Medicine & Dentistry. “Within the same plant, you’ve got two different chemicals that are producing opposite effects in terms of psychiatric effects, molecular signaling and effects on the dopamine pathway.”

Using pre-clinical models in rodents, Laviolette and his team, led by postdoctoral fellow Justine Renard, PhD, showed that CBD can normalize schizophrenia-like disturbances in the brain’s dopamine system. By doing so, CBD alleviates schizophrenia-related symptoms linked to abnormal dopamine activity such as psychosis and cognitive problems. The researchers also demonstrated that the chemical is bypassing the molecular pathway in the brain that causes the negative side-effects typically seen in traditional antipsychotic medications.

“One of the biggest problems in treating schizophrenia is that there hasn’t been an effective new treatment on the market in a very long time,” said Laviolette. “The drugs on the market today have limited efficacy and horrible side effects; there is a desperate need for safer alternative medications.”

While CBD has shown promise as a treatment for schizophrenia in previous studies, this research is the first to show exactly how it acts on the brain to have positive results in mitigating psychiatric symptoms without causing the fatigue, lack of motivation and other side-effects associated with traditional medications.

“When we measured the molecular changes that happened in the brain, we found that the effects of CBD were bypassing traditional molecular pathways that are activated by antipsychotic drugs. We think that’s one of the reasons that it has better tolerability and fewer side-effects,” he said.

The findings are published in the journal Neuroscience.

  • Admin
Cannabidiol as a Therapeutic Agent for Skin Health

Cannabidiol as a Therapeutic Agent for Skin Health


The centrality of skin function to human health has meant that evolution endowed skin with complex biochemical networks of receptors and small molecules that continually survey and respond to inputs, and modify the reactions of resident cells to react to incoming information.

One such network is the skin endocannabinoid system (SkECS), where endogenous and exogenous cannabinoids can act at numerous receptor sites to promote skin health. Cannabinoid receptors (CB1, CB2, TRPV1, TRPA1 and TRPV4) are present on multiple cell types in the human skin (fibroblasts, keratinocytes, immune cells, neurons, subcutaneous fat cells and muscle layers).

The presence of the SkECS is a clear indicator that cannabinoids may be central to skin health. It also presents the intriguing possibility that exogenously applied cannabinoids could augment, initiate or supplement the roles that endocannabinoids play in the skin to therapeutic benefit.

Cannabinoids and their diverse receptors have been implicated in the proliferation of skins cells, in the differentiation processes that give rise to the multicellular complexity of skin, in hormone and mediator secretion that maintain skin tone, and in the activity of hair follicle cells and the sebaceous glands.

The SkECS maintains skin homeostasis, and loss of this homeostasis leads to disorders such as acne, dermatitis, itch, pain, psoriasis, sclerosis and excessive or unwanted hair growth.


Epidermis – psoriasis – Phyto-cannabinoids inhibit keratinocyte proliferation, decrease keratinization and suppress cornified envelop formation; promote epidermal differentiation; inhibit proliferation of transformed (tumorigenic) keratinocytes.

Sebaceous glands – CB2 ligands stimulate lipid and sebum production and apoptosis of glandular cells.
Hair follicles – Anandamide inhibits hair shaft elongation and proliferation, promote intraepithelial apoptosis and catagen regression.

Dermatitis – Cannabinoid receptors suppress inflammation.

Dermal fibrosis – Cannabinoid receptors suppress fibrosis.

UV-B induced skin tumors and skin inflammation – Cannabinoid receptors suppress UV-B induced skin tumors and skin inflammation, resulting in decreased growth, angiogenesis, metastasis and apoptosis.

Sources and acknowledgments
“Evolved To Defend: Cannabinoid Protection Of Barrier Tissues In Plants And Humans”. Andrea L. Small-Howard, Ph.D.

  • Admin